Viewing stories from February, 2017

27 February 2017
Interim Report and Half-Yearly Financial Results

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

 

Financial Summary

  • Reported loss of $9.0M (Dec 2015: $10.0M)
  • R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
  • Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
  • Receipt of $3.5M R&D tax incentive refund from FY16
Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.